{"schema_version":"secwatch.filing_event.v1","accession":"0001600620-26-000015","form_type":"8-K","ticker":"AUPH","cik":"0001600620","company_name":"Aurinia Pharmaceuticals Inc.","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.597346+00:00","generated_at":"2026-05-15T23:37:04.041763+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Aurinia Q4 revenue up 29% to $77.1M, EPS $1.53; guides 2026 LUPKYNIS sales $305M-$315M","bullets":["LUPKYNIS net product sales for FY 2025: $271.3M, up 25% YoY; Q4 $74.2M, up 29%.","Net income for FY 2025: $287.2M ($2.07 diluted EPS) vs $5.8M ($0.04) in 2024; includes $173.0M tax benefit.","Cash, equivalents, restricted cash & investments: $398.0M at Dec 31, 2025; generated $135.7M from operations.","2026 guidance: total revenue $315M-$325M; LUPKYNIS net sales $305M-$315M (12-16% growth).","Initiated clinical study of aritinercept (BAFF/APRIL inhibitor); plan another autoimmune study in H1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001600620-26-000015","json":"https://secwatch.observer/filing/0001600620-26-000015.json","markdown":"https://secwatch.observer/filing/0001600620-26-000015.md","text":"https://secwatch.observer/filing/0001600620-26-000015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1600620/000160062026000015/0001600620-26-000015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1600620/000160062026000015/auph-20260226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:37:04.041763+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}